Busulfan Injection, 60 mg recall — Sagent Pharmaceuticals (Class III)

Sagent Pharmaceuticals is recorded by the U.S. Food and Drug Administration (FDA) as recalling Busulfan Injection, 60 mg — a Class III recall, initiated 2026-05-04 and posted to the FDA enforcement report on 2026-05-27, under recall number D-0539-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed Impurities/Degradation Specifications”. From the product description, the form is injection, the strengths given are 60 mg, 10 mL and 6 mg and it is marked Rx only. 1 National Drug Code number is printed in the record: 25021-241-10. Distribution is recorded as “Nationwide within the United States” — Nationwide (US), with the recalling firm on record in IL, United States. It is the only recall number the FDA has filed under event ID 98883. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0539-2026
FDA event ID 98883
Classification Class III (least serious regulatory tier)
Status Ongoing
Recalling firm Sagent Pharmaceuticals
Recall initiated 2026-05-04
Reported by FDA 2026-05-27
Report lag 23 days from initiation to report
Distribution Nationwide within the United States — Nationwide (US)
Firm location on record IL, United States
Product description (source) Busulfan Injection, 60 mg per 10 mL (6 mg per mL), 8x10 mL Single-Dose Vials, Rx only, Mfd. for Sagent Pharmaceuticals, Schaumburg, IL 60195, Made in Canada, NDC 25021-241-10.

Reason reported by FDA

Failed Impurities/Degradation Specifications

3 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

7 identifying values matched by exact pattern in the 29-word product description above; each is a literal substring of it.

Product named Busulfan Injection
Form Injection
Strength 60 mg · 10 mL · 6 mg
NDC 25021-241-10
Marketing category Rx only
Stated origin Canada

Reported in the same month (2026-05)

48 enforcement reports carry a report date in 2026-05; these 8 are the Class III ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Primidone Tablets USP, 250mgD-0533-2026Lannett Company Inc.Class III2026-05-27
Primidone Tablets, 50 mgD-0534-2026Golden State Medical Supply Inc.Class III2026-05-27
Primidone Tablets, 250 mgD-0535-2026Golden State Medical Supply Inc.Class III2026-05-27
Primidone Tablets, 250 mgD-0536-2026Amerisource Health Services LLCClass III2026-05-27
Primidone Tablets, 50 mgD-0537-2026Amerisource Health Services LLCClass III2026-05-27
busPIRone Hydrochloride Tablets, 5 mgD-0511-2026Unichem Pharmaceuticals Usa Inc.Class III2026-05-13
Levocarnitine Injection, 1 g/5 mLD-0494-2026American Regent, Inc.Class III2026-05-06
Lidocaine Wound Gel, 0.13%D-0509-2026Water-jel Technologies, LLCClass III2026-05-06

Nearest Class III recalls by date

25 of 250 indexed records share the Class III tier; the 8 nearest to 2026-05-27 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Nicotine Transdermal System Patch, 14 mgD-0550-2026Aveva Drug Delivery Systems, Inc.14 mg · Transdermal System2026-06-03
PRED MILD, 0.12%D-0551-2026Abbvie Inc.0.12% · Ophthalmic Suspension2026-06-03
Lidocaine HCl Injection, 2%D-0552-2026Eugia US LLC2% · Injection2026-06-10
Epinephrine Injection, 1mg/mLD-0581-2026Fresenius Kabi Usa, LLC1mg/mL · Injection2026-06-17
Primidone Tablets, 50 mgD-0585-2026Amneal Pharmaceuticals, LLC50 mg · Tablets2026-06-17
Premier, 8 mLD-0490-2026Premier Dental Products Co8 mL · Solution2026-04-29
Focalin XR (dexmethylphenidate HCl) 5 mgD-0608-2026Sandoz Inc5 mg · Extended-Release Capsules2026-06-24
hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mLD-0619-2026Ani Pharmaceuticals, Inc.10 mg/5 mL · Oral Solution2026-07-01

Reading this record

Class III is the FDA's own severity tier for the recall action — 25 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 25021-241-10 at the FDA source to confirm it is covered.

Namespace context: the Class III index (25 records) and the recall hub (250 records, 118 FDA events); Sagent Pharmaceuticals (6 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0539-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0539-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-05-27
Ingested
2026-08-22
Record hash
a158fa6d903fa98c

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.